Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ocular Therapeutix (OCUL) Gross Profit (2016 - 2025)

Ocular Therapeutix (OCUL) has 12 years of Gross Profit data on record, last reported at -$35.7 million in Q4 2025.

  • For Q4 2025, Gross Profit fell 671.71% year-over-year to -$35.7 million; the TTM value through Dec 2025 reached -$2.0 million, down 104.99%, while the annual FY2025 figure was -$2.0 million, 108.91% down from the prior year.
  • Gross Profit reached -$35.7 million in Q4 2025 per OCUL's latest filing, down from $12.8 million in the prior quarter.
  • Across five years, Gross Profit topped out at $32.9 million in Q4 2023 and bottomed at -$35.7 million in Q4 2025.
  • Average Gross Profit over 5 years is $6.8 million, with a median of $10.3 million recorded in 2022.
  • Peak YoY movement for Gross Profit: surged 1697.72% in 2022, then tumbled 671.71% in 2025.
  • A 5-year view of Gross Profit shows it stood at -$11.3 million in 2021, then surged by 215.42% to $13.1 million in 2022, then surged by 151.75% to $32.9 million in 2023, then plummeted by 81.02% to $6.2 million in 2024, then crashed by 671.71% to -$35.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Gross Profit were -$35.7 million in Q4 2025, $12.8 million in Q3 2025, and $11.5 million in Q2 2025.